Literature DB >> 30036234

Differences Between Pulmonary and Extrapulmonary Pediatric Acute Respiratory Distress Syndrome: A Multicenter Analysis.

Chin Seng Gan1, Judith Ju-Ming Wong2, Rujipat Samransamruajkit3, Soo Lin Chuah1, Yek Kee Chor4, Suyun Qian5, Nattachai Anantasit6, Xu Feng7, Jacqueline Soo May Ong8, Phan Huu Phuc9, Suwannee Phumeetham10, Rehena Sultana11, Tsee Foong Loh2, Lucy Chai See Lum1, Jan Hau Lee2.   

Abstract

OBJECTIVES: Extrapulmonary pediatric acute respiratory distress syndrome and pulmonary pediatric acute respiratory distress syndrome are poorly described in the literature. We aimed to describe and compare the epidemiology, risk factors for mortality, and outcomes in extrapulmonary pediatric acute respiratory distress syndrome and pulmonary pediatric acute respiratory distress syndrome.
DESIGN: This is a secondary analysis of a multicenter, retrospective, cohort study. Data on epidemiology, ventilation, therapies, and outcomes were collected and analyzed. Patients were classified into two mutually exclusive groups (extrapulmonary pediatric acute respiratory distress syndrome and pulmonary pediatric acute respiratory distress syndrome) based on etiologies. Primary outcome was PICU mortality. Cox proportional hazard regression was used to identify risk factors for mortality.
SETTING: Ten multidisciplinary PICUs in Asia. PATIENTS: Mechanically ventilated children meeting the Pediatric Acute Lung Injury Consensus Conference criteria for pediatric acute respiratory distress syndrome between 2009 and 2015.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Forty-one of 307 patients (13.4%) and 266 of 307 patients (86.6%) were classified into extrapulmonary pediatric acute respiratory distress syndrome and pulmonary pediatric acute respiratory distress syndrome groups, respectively. The most common causes for extrapulmonary pediatric acute respiratory distress syndrome and pulmonary pediatric acute respiratory distress syndrome were sepsis (82.9%) and pneumonia (91.7%), respectively. Children with extrapulmonary pediatric acute respiratory distress syndrome were older, had higher admission severity scores, and had a greater proportion of organ dysfunction compared with pulmonary pediatric acute respiratory distress syndrome group. Patients in the extrapulmonary pediatric acute respiratory distress syndrome group had higher mortality (48.8% vs 24.8%; p = 0.002) and reduced ventilator-free days (median 2.0 d [interquartile range 0.0-18.0 d] vs 19.0 d [0.5-24.0 d]; p = 0.001) compared with the pulmonary pediatric acute respiratory distress syndrome group. After adjusting for site, severity of illness, comorbidities, multiple organ dysfunction, and severity of acute respiratory distress syndrome, extrapulmonary pediatric acute respiratory distress syndrome etiology was not associated with mortality (adjusted hazard ratio, 1.56 [95% CI, 0.90-2.71]).
CONCLUSIONS: Patients with extrapulmonary pediatric acute respiratory distress syndrome were sicker and had poorer clinical outcomes. However, after adjusting for confounders, it was not an independent risk factor for mortality.

Entities:  

Mesh:

Year:  2018        PMID: 30036234     DOI: 10.1097/PCC.0000000000001667

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.624


  3 in total

Review 1.  Pertinent clinical outcomes in pediatric survivors of pediatric acute respiratory distress syndrome (PARDS): a narrative review.

Authors:  Siew Wah Lee; Sin Wee Loh; Chengsi Ong; Jan Hau Lee
Journal:  Ann Transl Med       Date:  2019-10

Review 2.  Definition and global epidemiology of pediatric acute respiratory distress syndrome.

Authors:  Fernando Beltramo; Robinder G Khemani
Journal:  Ann Transl Med       Date:  2019-10

3.  The Clinical Characteristics of ARDS in Children With Hematological Neoplasms.

Authors:  Qiao Zhang; Wen-Ting Hu; Fan Yin; Han Qian; Ying Wang; Bi-Ru Li; Juan Qian; Yan-Jing Tang; Bo-Tao Ning
Journal:  Front Pediatr       Date:  2021-07-08       Impact factor: 3.418

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.